Stock Message Boards
ETF Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards Portfolio Channel


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
LLY Description — Lilly (Eli) & Co.

Eli Lilly discovers, develops, manufactures, and markets products in two business segments: human pharmaceutical products and animal health products. Co.'s human pharmaceutical products include: endocrinology products, neurosciences products, oncology products, and cardiovascular products. Co.'s animal health products is comprised of products for food animals, which include Rumensin®, a cattle feed additive, and Tylan®, an antibiotic used to control certain diseases in cattle, swine, and poultry; as well as products for companion animals, which include Trifexis® and Comfortis®, a chewable tablet that kills fleas and prevents flea infestations on dogs.

Company Name:  Lilly (Eli) & Co.
Website:  www.lilly.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding LLY:  82
Total Market Value Held by ETFs:  $3,211,489,317
Total Market Capitalization:  $80,668,000,000
% of Market Cap. Held by ETFs:  3.98%
 ETF   LLY Weight   LLY Amount 
 SPY   0.38%   $731,696,198         
 XLV   2.62%   $332,689,334         
 IVV   0.38%   $268,579,287         
 DVY   1.49%   $232,128,518         
 IWD   0.68%   $173,688,769         
 VTI   0.32%   $166,943,210         
 VYM   0.81%   $116,773,269         
 VTV   0.64%   $113,274,643         
 VHT   2.23%   $104,694,758         
 VOO   0.37%   $103,449,043         
List of all 82 ETFs holding LLY »
10 ETFs With Stocks That Insiders Are Buying
25 Dividend Giants Widely Held By ETFs
25 S.A.F.E. Dividend Stocks Increasing Payments For Decades
Broker Darlings: Top 15 Analyst Picks of the Dow
Top 25 Broker Analyst Picks of the S&P 500
Forgotten S&P 500 Giants: Analysts' Current Least Favorites
25 Top Ranked Socially Responsible Dividend Stocks
10 Oversold ETFs
The Top 10 DividendRank'ed Stocks
The DividendRank Top 25
The Top 10 DividendRank'ed DJIA Components
The Top 10 DividendRank'ed Dow Transports Components
The Top 10 DividendRank'ed Dow Utilities Components
The Top 10 DividendRank'ed Nasdaq 100 Components
10 Stocks Going Ex-Dividend
10 Oversold Dividend Stocks
10 Stocks Where Yields Got More Juicy
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Top Ranked Dividend Stocks With Insider Buying
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Metals Stocks You Can Buy Cheaper Than Insiders Did
10 Oversold Metals Stocks
10 Must-Know High-Yield REITs
10 Top DividendRank'ed Financials
10 Top DividendRank'ed Metals Stocks
10 Oversold Energy Stocks
10 Top DividendRank'ed Energy Stocks
10 Top DividendRank'ed Utility Stocks
10 Stocks Crossing Below Book Value
10 Stocks Crossing Above Their 200 Day Moving Average
10 Stocks Crossing Below Their 200 Day Moving Average
10 ETFs Crossing Above Their 200 DMA
The 10 Biggest ETFs
The 10 Best ETF Performers
The 10 Worst ETF Performers
10 ETFs With Notable Inflows
10 ETFs With Notable Outflows
The Top 10 DividendRank'ed Canadian Stocks
The DividendRank Canada Top 25
10 Canadian Stocks Going Ex-Dividend
10 Oversold Canadian Stocks
10 Canadian Stocks Where Yields Got More Juicy
10 Must-Know High-Yield Canadian Real Estate Stocks
10 Top DividendRank'ed Canadian Financials
10 Must-Know High-Yield Canadian Energy Stocks
10 Canadian Stocks Crossing Below Book Value
10 Canadian Stocks Crossing Above Their 200 Day Moving Avg
10 Canadian Stocks Crossing Below Their 200 Day Moving Avg
Stock market game
Quotes delayed 20 minutes

Buy (2.90 out of 4)
38th percentile
(ranked lower than approx. 62% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite


PARTNER NEWS:

Mon, Dec 22, 1:50 PM, Zacks
Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - Analyst Blog
Eli Lilly and Company (LLY) and Adocia entered into a licensing agreement to develop an ultra-rapid insulin, BioChaperone Lispro, for type I and type II diabetes.

Wed, Dec 10, 4:20 PM, Zacks
Incyte (INCY) Gains on Positive Baricitinib Study Results - Analyst Blog
Incyte (INCY) and Eli Lilly (LLY) announced encouraging results from the phase III RA-BEACON study on baricitinib.

ETFs Holding LLY | Lilly (Eli) & Co. | ETF Channel | www.ETFChannel.com | Copyright © 2009 - 2014, All Rights Reserved

Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.